Clinical trial
GM1 Ganglioside Effects on Parkinson's Disease
NCT00037830 · Thomas Jefferson University, Other · Completed
Key facts
| NCT number | NCT00037830 |
|---|---|
| Title | GM1 Ganglioside Effects on Parkinson's Disease |
| Official title | The Study of GM1 Ganglioside, A Potential New Parkinson's Disease Medication |
| Lead sponsor | Thomas Jefferson University, Other |
| Collaborators | National Institute of Neurological Disorders and Stroke (NINDS) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Parkinson Disease |
| Intervention type | Drug |
| Interventions | GM1 ganglioside, Placebo |
| Enrollment | 94 |
| Start date | Nov 1, 1999 |
| Primary completion | Jun 1, 2010 |
| Completion | Jun 1, 2010 |
| First posted | May 23, 2002 |
| Last update posted | Dec 21, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: